Symptoms of Tardive Dyskinesia

Involuntary movements may affect different parts of a patient’s body, and they are called Tardive Dyskinesia. Common symptoms include:

1. Facial Movements: Common is involuntary grimace, lip smack and protruded tongue.

2. Limb Movements: Pain and jerking or twisting movements of the arms and legs are possible for patients.

3. Trunk Movements: Some individuals may have abnormal postures or movements of the torso.

These symptoms can have an insidious onset and for months or even years after the initiation of treatment with dopamine receptor antagonists, especially antipsychotic medications. Stress or anxiety makes the movements worse, and the movement can be very socially embarrassing and induce emotional distress in those experiencing the movements.

Causes of Tardive Dyskinesia

Long term use of medications that block dopamine receptors, specifically antipsychotics, is the main cause of Tardive Dyskinesia. They are usually prescribed for such conditions as schizophrenia, bipolar disorder and severe depression.

Other potential causes include:

1. Antiemetic Medications: In older adults, TD also can occur from drugs like Metoclopramide or Prochlorperazine.

2. Exposure to Neurotoxins: Some environmental toxins may play a role in movement disorder development.

3. Genetic Predisposition: Indeed, genetic factors may contribute to TD susceptibility, in particular variations in the dopamine receptor D2 gene.

Risk Factors for Tardive Dyskinesia

Certain groups are at a higher risk for developing Tardive Dyskinesia:

1. Age: Older adults are more susceptible, especially those over 55.

2. Gender: It seems to be mainly women that has gone through menopause who are at a higher risk, rather than men.

3. Duration of Treatment: TD is substantially more likely with prolonged exposure to antipsychotic medications.

4. Type of Antipsychotic: Newer (atypical) antipsychotics are less likely than traditional (typical) antipsychotics to cause the TD.

5. History of Movement Disorders: TD may develop in people with a history of movement disorders.

Diagnosis of Tardive Dyskinesia

Diagnosing Tardive Dyskinesia can be challenging, as the symptoms may be mistaken for other movement disorders or side effects of medication. A thorough clinical evaluation is necessary, typically involving the following:

1. Medical History: The patient’s history of antipsychotic use is reviewed by a doctor. Diagnosis relies on accurate timing of onset of symptoms, because TD usually occurs after prolonged exposure to these drugs.

2. Physical Examination: A detailed neurological examination is performed in the patient to see the nature and extent of involuntary movements. Physicians will rate symptoms with standard assessment tools (such as Abnormal Involuntary Movement Scale, AIMS).

3. Exclusion of Other Conditions: This must be confirmed, in other words, by ruling out other causes of involuntary movements, such as Parkinson’s disease, Huntington’s disease, or other neurological disorders.

Treatment Options for Tardive Dyskinesia

While there is no definitive cure for Tardive Dyskinesia, several treatment options can help manage symptoms:

1. Medication Adjustments: Symptoms may be reduced or decreased by discontinuing or reducing the offending medication. Unless done carefully under medical supervision this must not be done.

2. Medications for TD: Newer medications approved by FDA specifically for treating Tardive Dyskinesia are newer medications like Valbenazine and Deutetrabenazine. And these drugs are designed to work by altering how dopamine interacts with its receptors in the brain and have had some success in blocking involuntary movements.

3. Supportive Therapies: However, the following medications have no evidence of effectiveness in preventing of Tardive Dyskinesia and may help to restore motor function: Ginkgo biloba, Melatonin, Vitamin B6, Vitamin E.

Prevention of Tardive Dyskinesia

Preventing Tardive Dyskinesia primarily involves careful management of medications:

1. Regular Monitoring: The early signs of TD should be monitored in patients on long-term antipsychotic therapy.

2. Medication Alternatives: Whenever possible, healthcare providers should choose among atypical antipsychotics with a lower risk profile for treating TD.

3. Patient Education: Employing of patients and their families can inform them about risk associated with long term use of dopamine antagonists which can enable them to talk to their attendants about their treatment plans.